-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2568 Dexamethasone Versus Prednisolone in Adults with Newly Diagnosed Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Health outcomes research
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Karan Srisurapanont, MD1*, Ekdanai Uawithya, MD2*, Pojsakorn Danpanichkul, MD3*, Rinrada Worapongpaiboon, MD4* and Chatree Chai-Adisaksopha, M.D., Ph.D.1,5*

1Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
2Division of Neurology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
4Department of Medicine, Ratchaburi Hospital, Bangkok, Thailand
5Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand

Whether dexamethasone or prednisolone is the optimal first-line treatment in adults with newly diagnosed immune thrombocytopenia (ITP) remains controversial. We aimed to compare the efficacy and safety of dexamethasone and prednisolone in adults with newly diagnosed ITP. A systematic review and meta-analysis of randomized controlled trials (RCTs).

We searched Pubmed, Scopus, Cochrane Central Register of Controlled Trials, and Embase to identify relevant citations until May 16, 2024. RCTs comparing dexamethasone to prednisolone in adults with newly diagnosed ITP were included. The outcomes included early response (ER) at 1 week, initial response (IR) at 1 month, durable response (DR) at 6 months, persistent response (PR) at 12 months, and adverse events. The outcomes were pooled using the random-effect Mantel–Haenszel meta-analysis and reported as relative risks (RRs) alongside corresponding 95% confidence intervals (CIs). The certain of evidence of each outcome was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

We included 8 RCTs with 427 and 404 participants receiving dexamethasone and prednisolone, respectively. Dexamethasone yielded higher IR rates than prednisolone (RR 1.21, 95% CI 1.09-1.34). However, there was no improvement in terms of ER, DR, and PR. No significant difference was observed between 1-2 cycles and 3 cycles of dexamethasone in terms of IR (p=0.23), DR (p=0.64), and PR (p=0.88). Adverse events occurred more frequently in the prednisolone arm (141 events) than the dexamethasone arm (71 events), but the number of patients who discontinued the treatment was similar between both arms.

Very low certainty of evidence suggests that dexamethasone may be preferred compared to prednisolone in newly diagnosed adults with immune thrombocytopenia. Our findings suggested that one cycle of dexamethasone with a possible rescue course could be the optimal dosage.

Disclosures: No relevant conflicts of interest to declare.

See more of: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH